cisplatin injection solution
fresenius kabi canada ltd - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents
cisplatin injection bp solution
hikma canada limited - cisplatin - solution - 1mg - cisplatin 1mg
cisplatin injection, mylan std. solution
mylan pharmaceuticals ulc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents
cisplatin injection, powder, lyophilized, for solution
wg critical care, llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin for injection is indicated for the treatment of advanced testicular cancer. cisplatin for injection is indicated for the treatment of advanced ovarian cancer. cisplatin for injection is indicated for the treatment of advanced bladder cancer. cisplatin for injection is contraindicated in patients with severe hypersensitivity to cisplatin [see warnings and precautions (5.4)] . risk summary based on human data from published literature, cisplatin for injection can cause fetal harm when administered to pregnant women. advise pregnant women and females of reproductive potential of the potential risk to a fetus. data demonstrates transplacental transfer of cisplatin. exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth. cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. cisplatin for injection administration to animals during and after organogenesi
cisplatin accord
pharmacy retailing (nz) ltd t/a healthcare logistics - cisplatin 1 mg/ml; - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - cisplatin accord injection is indicated for the palliative treatment of: · metastatic non-seminomatous germ cell carcinoma; · advanced-stage refractory ovarian carcinoma; · advanced-stage refractory bladder carcinoma; and · refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, e.g. radiotherapy or surgery.
cisplatin injection bp solution
pfizer canada ulc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents
cisplatin injection, solution
bluepoint laboratories - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal impairment. cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum-containing compounds.
cisplatin injection, solution
fosun pharma usa inc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, s
cisplatin-faulding 1mg/ml
pharmaplan (pty) ltd - cisplatin - injection - cisplatin injection, 1mg/ml
cisplatin sterile concentrate injection 50 mg/50 ml oncotain
hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; mannitol; hydrochloric acid - cisplatin is used in the treatment of certain types of cancer, for example ovarian cancer, testicular cancer, bladder cancer and head and neck cancer. cisplatin may be used in combination with other anti-cancer medicines.